prognostic significance of pd-l1 and pten expression in prostatic cancer

Background: programmed death- ligand 1(pd-l1) acts as an immune checkpoint inhibitor. phosphatase and tensin homolog (pten) is a somatically mutated tumor suppressor gene in numerous types of human cancer. the current study aimed to assess the prognostic value of pd-l1 and pten expression in prostatic cancer patients, as well as their relationship with the clinicopathological features of the disease.method: a total of 55 needle biopsy specimens were retrospectively diagnosed as prostatic adenocarcinoma. immunohistochemical staining with pd-l1 and pten were evaluated in all the cases. the patients were followed up for 5 years in order to detect disease recurrence and survival.results: pd-l1 expression in prostate cancer was positively correlated with high prostatic specific antigen (psa), higher gleason score, advanced stage, higher tumor relapse, and worse disease-free and overall survival (p < 0.001). pten loss was significantly associated with high psa, higher gleason score < 7, advanced tumor stage, tumor relapse, and worse disease-free and overall survival (p < 0.001). we observed a significant negative correlation between pten and pd-l1.conclusion: pdl-1 and pten are prognostic markers for prostate cancer, which can differentiate between the patients who are at a high risk of disease progression and may successively provide novel targeted therapies.